Why is "Bcr-Abl" trending?

Search Interest Perspective

• Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design - American Heart Association Journals
• Localization of p210 BCR‐ABL to the Mitochondria Promotes Chronic Myeloid Leukemia Cell Proliferation Through cIAP Signaling - Ikegami - 2026 - Wiley & Sons
• BCR::ABL1-Rearranged Chronic Myeloid Leukemia: Molecular Basis, TKI Resistance and Emerging Therapies - Oncodaily
• Chronic Myeloid Leukemia (CML): Background, Pathophysiology, Epidemiology - Medscape
• Rethinking CML Care Delivery From Prescription to Persistence - Pharmacy Times – Pharmacy Practice News and Expert Insights
• Merck Bolsters Cancer Pipeline with $6.7B Terns Buyout - Genetic Engineering and Biotechnology News
• Chinese scientists describe new Bcr-Abl kinase inhibitors - BioWorld News
• Novel e4a2 BCR∷ABL1 transcript with insertion of CSE1L exons 9 and 10 in a CML patient: a case report - Frontiers
• Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data - American Heart Association Journals
• Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML - Novartis
• Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia - Nature
• Next generation therapies for chronic myeloid leukemia - Drug Discovery News
• An Overview of Chronic Myeloid Leukemia Treatment: From Tyrosine Kinase Inhibitors to Novel and Emerging Therapies - Wiley Online Library
• EU Backs Kinase Inhibitor Use in Initial Ph+ ALL Therapy - Medscape
• The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib | Leukemia - Nature
• Timing and trajectory of BCR::ABL1- driven chronic myeloid leukaemia - Nature
• Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells - Nature
• Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase - Nature
• Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets - Nature
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification - Science | AAAS
• Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia - Nature
• CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells - Nature
• Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients - Nature
• BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP - Nature
• Charting the molecular network of the drug target Bcr-Abl - PNAS
• GPX1 confers resistance to metabolic stress in BCR/ABL-T315I mutant chronic myeloid leukemia cells - Nature
• Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains - PNAS
• Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib - Science | AAAS
• Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy - Nature
• BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia - Frontiers
• Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis - Nature
• BCR-ABL Ratios in Patients with CML - Targeted Oncology
• Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study | Leukemia - Nature
• Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold - Nature
• Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia - The New England Journal of Medicine
• Case report: BCR-ABL-positive acute lymphoblastic leukemia with bone destruction: a treatment dilemma - Frontiers
• Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia - Nature
• Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells - Nature
• Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia - Nature
• Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia - Nature
• Higher-order interactions of Bcr-Abl can broaden chronic myeloid leukemia (CML) drug repertoire - Wiley Online Library
• Flying under the radar: the new wave of BCR–ABL inhibitors - Nature
• A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9 - PNAS
• Researchers Evaluate the Prognostic Importance of BCR-ABL Transcripts in Chronic Myeloid Leukemia - Cancer Nursing Today
• Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia - Nature
• Addressing Fluctuating BCR-ABL Levels in CML - OncLive
• Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome - The New England Journal of Medicine
• Role of Vitamins A and D in BCR-ABL Arf−/− Acute Lymphoblastic Leukemia | Scientific Reports - Nature
• A Rare Case of Myelofibrosis Progressing to BCR-ABL1-Positive Chronic Myeloid Leukemia With Discordant Molecular Testing - Cureus
• BCR/ABL1 –like acute lymphoblastic leukemia: How to diagnose and treat? - Wiley & Sons
• Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure - The New England Journal of Medicine
• STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia - The Lancet
• Characteristics and outcome of patients with Philadelphia chromosome negative, bcr abl negative chronic myelogenous leukemia - Wiley & Sons
• TERN-701 Decreases BCR-ABL Levels, Generates Molecular Responses in R/R CML - OncLive
• Allosteric inhibitors of Bcr-abl–dependent cell proliferation - Nature
• BCR-ABL %IS Kit Monitors CML Treatment Response - Clinical Lab Products
• Blinatumomab-Based Consolidation Is a New Standard in BCR/ABL-Negative B-ALL - Oncology News Central
• AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL - Nature
• Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia - Nature
• Managing BCR-ABL Inhibitor Associated Skin Rash - OncLive
• BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia - Nature
• PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis - Nature
• Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin - Haematologica
• Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors - Nature
• BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia | Oncogene - Nature
• BCR-ABL Cutoffs at 3 Months Could Influence CML Treatment - CancerNetwork
• Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi) - Nature
• New-Generation BCR-ABL TKIs Linked to Increased Risk of Hepatotoxicity in Patients With Chronic Myeloid Leukemia - Oncology Nurse Advisor
• New ABL1 Kinase Domain Mutations in BCR::ABL1‐Positive Acute Lymphoblastic Leukemia - Wiley Online Library
• BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia - The New England Journal of Medicine
• The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors - Wiley & Sons
• The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein - PNAS
• Doctors Debate: Is Intensive or Low-Intensity Chemotherapy Plus BCR-ABL TKI Therapy Best for Treatment of Ph+ ALL? - Targeted Oncology
• Bcr-Abl drives the formation of Hsp70/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis - ScienceDirect.com
• Novel Therapies for T315I-Mutant Chronic Myeloid Leukemia - OncLive
• Human BCR/ABL1 induces chronic myeloid leukemia-like disease in zebrafish - Haematologica
• Regulation of the c-Abl and Bcr–Abl tyrosine kinases - Nature
• BCR–ABL1 expression in multiple myeloma cells: A case of mistaken identity? - PNAS
• BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2 - Nature
• How to Select the Optimal BCR-ABL TKI Therapy for Treatment of Chronic-Phase CML - Oncology Nurse Advisor
• Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate - Nature
• Protein kinase CKIIα interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells - Nature
• Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph - PNAS
• A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance - PNAS
• BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study - The Lancet
• Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells - Nature
• Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia - Frontiers
• Rapid BCR-ABL Reduction Is Predictive of Response in CML - CancerNetwork
• BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia - The New England Journal of Medicine
• Stopping TKI Treatment Is Safe, Improves Quality of Life for Some with CML - National Cancer Institute (.gov)
• BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac - PNAS
• Treatment Advances Transform CML Into Chronic Disease - Cure Today
• Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: - American Heart Association Journals
• Sudden Blast Crisis After Excellent Initial Response in Chronic Myeloid Leukemia - Cureus
• Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase - PNAS
• Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy - Haematologica
• BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations - Nature
• Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia - The New England Journal of Medicine
• The age incidence of chronic myeloid leukemia can be explained by a one-mutation model - PNAS
• Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1 - Wiley Online Library